证券代码：300981 证券简称：中红医疗 公告编号：2024-062 为进一步加强与投资者的互动交流，中红普林医疗用品股份有限公司（以下 简称"公司"）将参加由河北证监局、河北上市公司协会与深圳市全景网络有限 公司联合举办的"2024 年度河北辖区上市公司投资者网上集体接待日暨 2024 年 半年报业绩说明会活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (http://rs.p5w.net)，或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2024 年 10 月 15 日（周二）15:30-17:00。 届时公司总经理杨浩女士、副总经理兼财务总监王文龙先生、董事会秘书张 琳波先生将在线就公司业绩、公司治理、发展战略、经营状况和可持续发展等投 资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与。 特此公告。 中红普林医疗用品股份有限公司 董事会 中红普林医疗用品股份有限公司 关于参加 2024 年河北辖区上市公司投资者网上集体接待日 暨 2024 年半年报业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的 ...

证券代码：300981 证券简称：中红医疗 公告编号：2024-061 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 变更注册的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 上述医疗器械注册证的相关变更，是在原有注册证的基础上根据相关要求进 行相应的变更，延续和丰富了公司及子公司在一次性使用输液器（带针）领域的 产品品类，有利于进一步提高市场应用拓展能力，进而增强公司及子公司的综合 竞争力。 上述产品实际销售情况取决于未来市场的推广效果，产品销售及利润贡献具 有不确定性，目前尚无法预测上述产品对公司未来业绩的影响，敬请投资者注意 防范投资风险。 三、备查文件 特此公告。 中红普林医疗用品股份有限公司 董事会 二〇二四年十月八日 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司（以下简称"科伦医械"）于近期取得国家药品监督管理局颁 发的《医疗器械变更注册（备案）文件》。根据 GB 8368-2018 的相关要求，科伦 医械对原有注册证在结构及组成、型号规格、产品技术要求方面进行了变更 ...

Investment Rating - The report assigns an "Outperform" rating to the company [2]. Core Insights - The report highlights the recovery of the glove industry, with new business lines gradually gaining traction. The company has diversified its product lines and is well-positioned to mitigate risks associated with single product cycles [5][10]. - The company has made strategic acquisitions to enhance its product offerings, including entering higher-margin markets such as medical surgical gloves and condoms [5][37]. - Future growth is expected to come from emerging markets, where demand for disposable gloves is anticipated to increase significantly [16][24]. Summary by Sections Company Overview - The report discusses the company's rapid development since its establishment in 2010 and its diverse product lines, including high-quality disposable health protection products and medical sterile instruments [10]. - The actual controller of the company is the Xiamen State-owned Assets Supervision and Administration Commission, holding 37.88% of the shares as of the end of 2023 [14]. Glove Market Analysis - The disposable glove market is currently in an adjustment phase, with supply and demand returning to normal. The report notes that the overall capacity utilization in the industry is improving, and profit margins for health protection products are expected to rise starting in the second half of 2023 [19][22]. - The report emphasizes the significant growth potential in developing countries, where per capita consumption of disposable gloves is still low compared to developed nations [23][24]. Product Diversification - The company has established three business divisions: Health Protection, Safe Infusion, and Innovation Incubation, which allows it to effectively manage market fluctuations [18]. - Recent acquisitions have strengthened the company's position in the disposable glove market and expanded its product range, including latex gloves and various condom products [37]. Financial Projections - The report forecasts earnings per share (EPS) of 0.29, 0.46, and 0.68 for the years 2024 to 2026, with a projected net profit growth rate of 187.1%, 58.8%, and 45.8% respectively [5][6].

证券代码：300981 证券简称：中红医疗 公告编号：2024-060 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司参与多个集中 带量采购项目拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）控股子公司江西科伦 医疗器械制造有限公司（以下简称"科伦医械"）于近期参加了甘肃省兰州市市 际联盟普通医用耗材集中带量采购和河北省一次性使用导尿包等 7 种医用耗材 带量联动采购项目的投标工作。根据甘肃省公共资源交易中心和河北省医用药品 器械集中采购中心官网拟中选结果相关公告显示，科伦医械部分产品拟中选上述 集中带量采购项目。现将相关情况公告如下： 三、风险提示 本次拟中选产品相关采购合同尚未签订，后续事项及对公司的影响程度具有 不确定性。公司将密切关注该事项的进展情况并及时履行信息披露义务，敬请广 大投资者谨慎决策，注意投资风险。 特此公告。 中红普林医疗用品股份有限公司 二、对公司的影响 科伦医械为公司安全输注事业部主要子公司，科伦医械一次性使用人体静脉 项目采购品种 注册 分类 产品 ...

证券代码：300981 证券简称：中红医疗 公告编号：2024-059 中红普林医疗用品股份有限公司 关于开立募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）于 2023 年 12 月 5 日 召开了第三届董事会第二十六次会议和第三届监事会第二十次会议，审议通过了 《关于 2024 年度拟使用暂时闲置超募资金及其利息进行现金管理暨关联交易的 议案》，同意公司 2024 年度在不影响募集资金投资项目建设和公司正常运营的 情况下，对暂时闲置超募资金及其利息在确定投资计划前进行现金管理，以增加 公司收益；使用闲置超募资金及其利息的额度不超过 9 亿元，其中涉及与世纪证 券有限责任公司关联交易的额度不超过 3 亿元，单个产品期限不超过十二个月， 资金可循环滚动使用，闲置募集资金现金管理到期后将及时归还至募集资金专户， 进行现金管理的投资产品包括但不限于结构性存款、定期存款、大额存单、收益 凭证和国债逆回购等安全性高、流动性好的保本型理财产品；董事会提请股东大 会授权董事长、总经理或其授 ...

海通证券股份有限公司关于中红普林医疗用品股份有限公司 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1、信息披露 | 无 | 不适用 | | 2、公司内部制度的建立和执行 | 无 | 不适用 | | 3、"三会"运作 | 无 | 不适用 | | 4、控股股东及实际控制人变动 | 无 | 不适用 | | 5、募集资金存放及使用 | 无 | 不适用 | | 6、关联交易 | 无 | 不适用 | | 7、对外担保 | 无 | 不适用 | | 8、收购、出售资产 | 无 | 不适用 | | 9、其他业务类别重要事项（包括对外投资、风险投 资、委托理财、财务资助、套期保值等） | 无 | 不适用 | | 10、发行人或者其聘请的中介机构配合保荐工作的情 况 | 无 | 不适用 | | 11、其他（包括经营环境、业务发展、财务状况、管 | | | | 理状况、核心技术等方面的重大变化情况） | 无 | 不适用 | 三、公司及股东承诺事项履行情况 2 | 公司及股东承诺事项 | 是否履行承诺 | 未履行承诺的原因及解 | | --- | --- | --- | | | | 决措施 ...

Financial Performance - The company's operating revenue for the reporting period reached ¥1,148,451,821.02, representing a 14.97% increase compared to ¥998,882,650.75 in the same period last year[13]. - The net profit attributable to shareholders was ¥32,529,868.67, a significant turnaround from a loss of ¥4,942,596.19 in the previous year, marking a 758.15% increase[13]. - The net cash flow from operating activities was negative at ¥84,900,776.67, a decline of 318.91% compared to a positive cash flow of ¥38,783,180.75 in the same period last year[13]. - Basic earnings per share improved to ¥0.0836 from a loss of ¥0.0127, reflecting a 758.27% increase[13]. - Total assets at the end of the reporting period amounted to ¥7,461,891,884.23, up 5.74% from ¥7,056,973,990.05 at the end of the previous year[13]. - The net assets attributable to shareholders decreased by 2.96%, totaling ¥5,597,112,677.39 compared to ¥5,768,086,190.12 at the end of the previous year[13]. - The company reported non-recurring gains and losses totaling ¥36,802,014.42 for the period[17]. - The company experienced a 90.42% reduction in net profit after deducting non-recurring gains and losses, resulting in a loss of ¥4,272,145.75[13]. - The weighted average return on net assets was 0.56%, an increase of 0.64 percentage points from -0.08% in the previous year[13]. - The company’s cash and cash equivalents increased by 93.28%, reaching ¥274,118,589.65 compared to ¥141,826,253.83 in the previous year[62]. Market and Industry Insights - The global medical device market was valued at $489 billion in 2021 and is projected to grow at a CAGR of 5.5%, reaching over $580 billion by 2025 and approximately $719 billion by 2029[19]. - The disposable health protection gloves market is experiencing a significant recovery, with domestic manufacturers seeing an increase in quality orders due to rising health awareness and demand in emerging markets[23]. - The safe infusion product market is stable, with a significant share in low-value medical consumables, driven by the number of hospital admissions and supported by government policies favoring domestic medical supplies[25]. - The company is positioned to benefit from the increasing focus on high-quality medical services and the expansion of the medical device market in China, as indicated by recent government reports[19]. - The medical device industry is expected to expand due to increasing health awareness and rising consumption levels in emerging markets, providing greater market potential for the company's main products[45]. Product Development and Innovation - The company is involved in the research and development of new medical products, although specific details are not provided in the content[2]. - The company is enhancing its product offerings in the life support category, including infusion pumps and monitoring systems, to meet the growing demand for advanced medical solutions[20]. - The company has developed over 100 different types of condoms, meeting various market demands and achieving full-category production and sales[30]. - The company has invested 8 years in R&D to produce the first barrier condom in 2019, which combines the elasticity of natural latex with modified polyurethane[38]. - The company has established five research institutes and collaborates with various universities and research institutions for product development and registration[44]. Compliance and Risk Management - The company emphasizes the importance of risk awareness regarding future plans, which depend on various factors including international political environment and market supply-demand relationships[2]. - The company acknowledges the potential risks it faces and has outlined measures to address these risks in its management discussion[2]. - The company is committed to maintaining compliance with international standards such as ISO13485 for medical device quality management[6]. - The company has received various international certifications, including FDA and CE, and exports to over 80 countries, indicating strong global market presence[29]. - The company has established a derivative investment management system to control risks associated with foreign exchange derivatives, ensuring compliance and effective management[83]. Environmental Responsibility - The company strictly adheres to various environmental protection laws and standards, ensuring compliance with pollutant discharge requirements[101]. - The company has established wastewater treatment facilities that consistently meet discharge standards, with online monitoring systems in place[104]. - The total investment in environmental governance and protection by the company and its subsidiaries for the first half of 2024 was approximately 8 million yuan[105]. - The company has not experienced any environmental pollution incidents during the reporting period[104]. - The company emphasizes a sustainable development approach, focusing on reducing waste and carbon emissions while increasing efficiency and production[107]. Corporate Governance and Shareholder Engagement - The company has a commitment to transparency, with all board members present for the review of the half-year report[1]. - The company held its annual general meeting on May 16, 2024, with a participation rate of 71.71%[99]. - The company has actively engaged with investors through various communication channels to enhance shareholder participation[105]. - The company has established a stock repurchase plan to stabilize its stock price, with conditions based on the audited net asset value per share[111]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[118]. Financial Management and Investments - The company has a strong cash flow and low debt-to-asset ratio, providing a solid financial foundation for new business development, mergers and acquisitions, and R&D investments[58]. - The company has engaged in cash management of idle raised funds amounting to RMB 651,000,000.00, generating interest income and investment returns of RMB 10,776,150.93 during the reporting period[76]. - The company has not made significant progress in major non-equity investments during the reporting period[71]. - The company has not reported any overdue amounts or uncollected funds from entrusted financial management during the reporting period[81]. - The company plans to continue investing in mergers and acquisitions to explore new market segments and innovate product offerings[46].

证券代码：300981 证券简称：中红医疗 公告编号：2024-054 中红普林医疗用品股份有限公司 第四届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2. 审议通过《关于 2024 年半年度计提减值准备的议案》 公司监事会认为：公司本次计提减值准备符合《企业会计准则》等相关规定 和公司实际情况。本次计提减值准备后，能够更加公允地反映公司经营状况，履 行的决策程序符合相关法律法规及《公司章程》的规定，不存在损害公司及全体 投资者利益的情形。 二、会议审议情况 1. 审议通过《关于<2024 年半年度报告及其摘要>的议案》 公司监事会认为：公司编制的《2024 年半年度报告》和《2024 年半年度报 告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 一、会议召开情况 表决结果为：同意 3 票，反对 0 票，弃权 0 票。 中红普林医疗用品股份有限公司（以下简称"公司"）第四届监事会第二次 （定期）会议于 2024 年 8 月 29 日以 ...

| | 中红普林（北京）医 疗用品高新技术研究 | 全资子公司 | 其他应收款 | 67.77 | 62.03 | | 129.80 | 日常经营资金 需求 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 院有限公司 | | | | | | | | | | | 中红医疗用品（海 | 全资子公司 | 其他应收款 | 1,942.65 | 2,560.00 | 1,570.00 | 2,932.65 | 日常经营资金 | 非经营性往来 | | | 南）有限公司 | | | | | | | 需求 | | | | 中红医疗用品（上 海）有限公司 | 全资子公司 | 其他应收款 | 74.97 | 249.00 | 214.32 | 109.65 | 日常经营资金 需求 | 非经营性往来 | | | 广西中红医疗用品有 限公司 | 全资子公司 | 其他应收款 | 1,335.00 | | | 1,335.00 | 日常经营资金 需求 | 非经营性往来 | | | 深圳迈德瑞纳生物科 | 控股子公司 | 其他应收款 ...

海通证券股份有限公司 一、募集资金基本情况 （一）募集资金实际到位及存放情况 经中国证券监督管理委员会《关于同意中红普林医疗用品股份有限公司首次 公开发行股票注册的批复》（证监许可[2021]758 号）同意注册，公司首次公开发 行人民币普通股（A 股）股票 41,670,000 股，每股面值 1.00 元，发行价为每股人 民币 48.59 元，募集资金总额为人民币 2,024,745,300.00 元，扣除发行费用总额 （不含增值税）人民币 128,288,946.26 元，实际募集资金净额为人民币 1,896,456,353.74 元。募集资金 1,917,800,968.44 元(含部分未划转发行费用)已于 2021 年 4 月 21 日到账至公司指定账户，容诚会计师事务所（特殊普通合伙）对 公司首次公开发行股票的资金到位情况进行了审验，并出具了《验资报告》（容 诚验字[2021]350Z0002 号）。公司对募集资金进行了专户存储管理。 为规范募集资金的管理和使用，切实保护投资者利益，公司根据《中华人民 共和国公司法》、《中华人民共和国证券法》和《深圳证券交易所创业板股票上市 关于中红普林医疗用品股份 ...